Drug intelligence / Profile preview

GSK4406371

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GSK4406371** is GSK's investigational live-attenuated measles, mumps, rubella, and varicella vaccine using a new seed strain. It is a tetravalent pediatric MMRV vaccine intended to induce protective immune responses against measles, mumps, rubella, and varicella. The candidate is in Phase II development, with studies assessing the immunogenicity and safety of different vaccine potencies in healthy children aged 4 to 6 years.

Beyond the preview

Go deeper on GSK4406371.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK4406371.

Explore the full profile